JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aandelen Lijst・Danaher Corp

Search

Danaher Corp

Gesloten

SectorGezondheidszorg

174.62 0.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

173.22

Max

176.42

Belangrijke statistieken
By Trading Economics
Inkomsten	-168M 1B
Verkoop	-887M 6B
K/W Sectorgemiddelde	34.936 67.147
EPS	2.06
Dividendrendement	0.77
Winstmarge	17.291
Werknemers	58,000
EBITDA	-514M 1.5B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+34.3% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	0.77% 2.36%
Volgende Winsten	21 jul 2026
Volgende dividenddatum	24 jul 2026
Volgende Ex Dividend datum	26 jun 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-11B 128B
Vorige openingsprijs	174.3
Vorige sluitingsprijs	174.62

Nieuwssentiment

By Acuity

23%

77%

76 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

189.8851 / 196.5 Steun & Weerstand

Danaher Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 apr 2026, 11:36 UTC

Winsten

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

21 apr 2026, 11:00 UTC

Winsten

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

21 apr 2026, 10:06 UTC

Winsten

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

21 apr 2026, 10:05 UTC

Winsten

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

21 apr 2026, 10:05 UTC

Winsten

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

21 apr 2026, 10:05 UTC

Winsten

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

21 apr 2026, 10:04 UTC

Winsten

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

21 apr 2026, 10:04 UTC

Winsten

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Cont Ops EPS $1.45 >DHR

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Adj EPS $2.06 >DHR

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Sales $5.95B >DHR

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q EPS $1.45 >DHR

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Net $1.03B >DHR

17 apr 2026, 19:15 UTC

Marktinformatie

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Marktinformatie

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 feb 2026, 20:06 UTC

Acquisities, Fusies, Overnames

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

17 feb 2026, 15:14 UTC

Acquisities, Fusies, Overnames

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

17 feb 2026, 14:39 UTC

Acquisities, Fusies, Overnames

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 feb 2026, 13:30 UTC

Acquisities, Fusies, Overnames

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 feb 2026, 13:15 UTC

Acquisities, Fusies, Overnames

Danaher Strikes $10 Billion Deal for Masimo -- Update

17 feb 2026, 13:03 UTC

Acquisities, Fusies, Overnames

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

17 feb 2026, 13:03 UTC

Acquisities, Fusies, Overnames

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

17 feb 2026, 13:02 UTC

Acquisities, Fusies, Overnames

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

17 feb 2026, 13:02 UTC

Acquisities, Fusies, Overnames

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

17 feb 2026, 13:02 UTC

Acquisities, Fusies, Overnames

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

17 feb 2026, 13:01 UTC

Acquisities, Fusies, Overnames

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

17 feb 2026, 13:00 UTC

Acquisities, Fusies, Overnames

Danaher to Buy Masimo for $180/Share >DHR MASI

17 feb 2026, 13:00 UTC

Acquisities, Fusies, Overnames

Danaher To Acquire Masimo Corporation >DHR MASI

17 feb 2026, 11:09 UTC

Acquisities, Fusies, Overnames

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

17 feb 2026, 11:09 UTC

Acquisities, Fusies, Overnames

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

Peer Vergelijking

Prijswijziging

Danaher Corp Prognose

Koersdoel

By TipRanks

34.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 233.74 USD 34.3%

Hoogste 270 USD

Laagste 184.04 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Danaher Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Gebaseerd op 16 analisten die aandelenratings hebben gegeven aan Danaher Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

189.8851 / 196.5Steun & Weerstand

Recent bullish events outweigh bearish events.

There is one bullish event.

The bullish and bearish events are balanced.

Sentiment

By Acuity

76 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Andere aandelen uit de sector

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat